SB-715992
information and resources from the National Cancer Institute
NCI Thesaurus | SB-715992
A synthetic small molecule with antineoplastic properties. SB-715992 selectively inhibits kinesin spindle protein (KSP), resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and cell death in tumor cells that overexpress KSP. NCI Thesaurus | SB-715992
A synthetic small molecule with antineoplastic properties. SB-715992 selectively inhibits kinesin spindle protein (KSP), resulting in inhibition of mitotic spindle assembly, induction of cell cycle arrest during the mitotic phase, and cell death in tumor cells that overexpress KSP.
|
|
|
|
news articles
Cytokinetics Reports Data for Ispinesib (SB-715992) in Platinum ... Mar 30, 2006
Yahoo! News (press release) The strategic alliance between Cytokinetics and GSK has yielded two novel drug candidates, ispinesib (SB-715992) and SB-743921. ...
Cytokinetics to Present at the Lehman Brothers Ninth Annual Global ... Mar 2, 2006
PR Newswire (press release), ...diseases. GSK is conducting Phase II and Ib clinical trials for ispinesib (SB-715992) and a Phase I clinical trial for SB-743921. ...
Cytokinetics Announces Selection of Development Candidate Directed ... Dec 13, 2005
PR Newswire (press release), The most advanced KSP inhibitor, ispinesib (SB-715992), is the subject of a broad clinical trials development program being conducted by GSK and the National ...
Cytokinetics Announces Seven Poster Presentations at the 45th ... Dec 14, 2005
Yahoo! News (press release) GlaxoSmithKline is conducting Phase II and Phase Ib clinical trials for ispinesib (SB-715992) and a Phase I clinical trial for SB-743921, each a drug candidate ...
(PRN) Cytokinetics Announces Presentation of Ispinesib Data at San ... Dec 8, 2005
Houston Chronicle, Incorporated (Nasdaq: CYTK) announced today that an interim analysis from an ongoing multicenter Phase II clinical trial of ispinesib (SB-715992) in subjects ...
Cytokinetics Announces Interim Phase II Breast Cancer Data for ... Dec 1, 2005
PR Newswire (press release), Cytokinetics, Incorporated (NASDAQ: CYTK) announced today that interim data from an ongoing Phase II clinical trial of ispinesib (SB-715992) in subjects with ...
Cytokinetics Announces Clinical and Non-Clinical Results for ... Nov 17, 2005
PR Newswire (press release), NASDAQ: CYTK) announced today that data from Phase Ib combination clinical trials and non-clinical studies of ispinesib (SB- 715992) were presented at the 2005 ...
|
|
